ATE397664T1 - Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität - Google Patents

Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität

Info

Publication number
ATE397664T1
ATE397664T1 AT01272818T AT01272818T ATE397664T1 AT E397664 T1 ATE397664 T1 AT E397664T1 AT 01272818 T AT01272818 T AT 01272818T AT 01272818 T AT01272818 T AT 01272818T AT E397664 T1 ATE397664 T1 AT E397664T1
Authority
AT
Austria
Prior art keywords
ability
amino acid
regulatory factor
transcription regulatory
studying
Prior art date
Application number
AT01272818T
Other languages
English (en)
Inventor
Norihisa Ohe
Original Assignee
Sumitomo Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co filed Critical Sumitomo Chemical Co
Application granted granted Critical
Publication of ATE397664T1 publication Critical patent/ATE397664T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT01272818T 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität ATE397664T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000398548 2000-12-27
JP2001077740 2001-03-19

Publications (1)

Publication Number Publication Date
ATE397664T1 true ATE397664T1 (de) 2008-06-15

Family

ID=26606895

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01272511T ATE393168T1 (de) 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung
AT01272818T ATE397664T1 (de) 2000-12-27 2001-12-17 Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität
AT01272819T ATE511539T1 (de) 2000-12-27 2001-12-17 Bhlh-pas-proteine, deren gene und verwendung derselben

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01272511T ATE393168T1 (de) 2000-12-27 2001-12-17 Transkriptionsaktivierungskomplex und dessen verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01272819T ATE511539T1 (de) 2000-12-27 2001-12-17 Bhlh-pas-proteine, deren gene und verwendung derselben

Country Status (6)

Country Link
US (3) US7129065B2 (de)
EP (3) EP1354889B1 (de)
AT (3) ATE393168T1 (de)
CA (3) CA2433501C (de)
DE (2) DE60134342D1 (de)
WO (3) WO2002053729A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke
WO2006026485A2 (en) 2004-08-25 2006-03-09 Isis Pharmaceuticals, Inc. Modulation of hif1-beta expression
JP2007282501A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd アポトーシス制御能力の検定方法
JP2007282502A (ja) * 2006-03-24 2007-11-01 Sumitomo Chemical Co Ltd 細胞変性制御能力の検定方法
US11889986B2 (en) 2010-12-09 2024-02-06 Endochoice, Inc. Flexible electronic circuit board for a multi-camera endoscope

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757524B1 (fr) * 1996-12-19 1999-01-29 Rhone Poulenc Rorer Sa Polypeptides de la famille bhlh, sequences d'acides nucleiques correspondantes
US5840532A (en) 1997-01-21 1998-11-24 Board Of Regents, The University Of Texas System Neuronal bHLH-PAS domain proteins
WO1999028464A2 (en) * 1997-11-28 1999-06-10 Wisconsin Alumni Research Foundation Cdnas and proteins belonging to the bhlh-pas superfamily of transcription regulators and methods of use
CA2453907A1 (en) * 2000-08-04 2002-02-14 Florida Atlantic University Association of sim2 with cancer
US20030190653A1 (en) * 2002-01-11 2003-10-09 Mehrdad Shamloo Regulated gene in the pathophysiology of ischemic stroke

Also Published As

Publication number Publication date
US20040110171A1 (en) 2004-06-10
WO2002053729A1 (fr) 2002-07-11
ATE511539T1 (de) 2011-06-15
CA2433495A1 (en) 2002-07-11
US20040248247A1 (en) 2004-12-09
EP1354951A4 (de) 2004-12-29
CA2433501C (en) 2011-07-19
EP1354946A4 (de) 2005-01-05
EP1354951A1 (de) 2003-10-22
DE60133774D1 (de) 2008-06-05
US7129065B2 (en) 2006-10-31
EP1354889B1 (de) 2008-04-23
EP1354889A4 (de) 2004-12-29
EP1354946A1 (de) 2003-10-22
DE60134342D1 (de) 2008-07-17
US20060216705A1 (en) 2006-09-28
WO2002053736A1 (fr) 2002-07-11
ATE393168T1 (de) 2008-05-15
DE60133774T2 (de) 2009-05-28
WO2002053735A1 (fr) 2002-07-11
CA2433492A1 (en) 2002-07-11
EP1354946B1 (de) 2011-06-01
EP1354889A1 (de) 2003-10-22
CA2433501A1 (en) 2002-07-11
EP1354951B1 (de) 2008-06-04
US7541189B2 (en) 2009-06-02
CA2433495C (en) 2011-10-18

Similar Documents

Publication Publication Date Title
ATE488588T1 (de) Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker
AU4483096A (en) A method of detecting biologically active substances
DE60035681D1 (de) Optische sonden und assays zur messung der proteinphosphorylierung
CA2403817A1 (en) Methods of modulating hair growth
ATE224457T1 (de) Verfahren zur identifizierung von nukleinsäuren, welche agenzien kodieren, die zelluläre phenotypen beeinflussen
EP1170380A3 (de) Zusammensetzungen und Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
IL157380A0 (en) Mediator stabilized reagent compositions and methods for their use in electrochemical analyte detection assays
WO2003078962A3 (en) Detection and quantification of modified proteins
DE59914830D1 (de) Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität
DE60126006D1 (de) Sonde, Zelle und Verfahren zur Messung der Konzentration und der Zusammensetzung von Biomasse
ATE397664T1 (de) Verfahren zur untersuchung der fähigkeit zur kontrolle der nervenzellplastizität
DK0670493T3 (da) Analyse til bestemmelse af protein i en biologisk prøve
ATE333091T1 (de) Verfahren zur messung von blutersatzstoffen
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
ATE350660T1 (de) Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression
DE60229593D1 (de) Verfahren zur Quantifizierung von Nukleinsäuren mittels Bestimmung der Zellzahl
ATE365326T1 (de) Verfahren zur analyse der menge an intraabdominalem fettgewebe
WO2009125936A3 (ko) 다낭성 난소 증후군 진단을 위한 분석방법 및 키트
ATE403877T1 (de) Verfahren zur untersuchung der aktivität von ionenkanälen
DE602005025226D1 (de) Verfahren zum zählen von bakterien, bakterienzählgerät und für das zählgerät vewendete zelle
DE60133708D1 (de) Verfahren zur Analyse von Nicht-Protein Komponenten mittels Verwendung einer Protease aus einem Bacillus-Stamm
Sesardic et al. Alternatives to the LD50 assay for botulinum toxin potency testing: Strategies and progress towards refinement, reduction and replacement
DE69938973D1 (de) Verfahren zur feststellung von einer thiol enthaltenden zusammensetzung
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
DE69635925D1 (de) Verfahren und testsatz zur evaluierung der metastasierungstendenz von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties